18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
Acupuncture Offers Quality-of-Life Benefits for Patients Taking AIs
July 30th 2014A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has shown that electroacupuncture produces significant improvements in fatigue, anxiety, and depression in as little as 8 weeks for early-stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors (AIs).
Trastuzumab-Associated Cardiac Events Reversible, Outweighed by Benefits
July 18th 2014Cardiac events associated with trastuzumab (Herceptin) are mostly reversible and outweighed by significant extensions in overall survival (OS) and progression-free survival (PFS) for patients with HER2-positive breast cancer
Dr. Jagsi on the Adoption of Hypofractionated Radiotherapy for Breast Cancer
June 24th 2014Reshma Jagsi, MD, DPhil, associate professor, Department of Radiation Oncology, University of Michigan Health System, discusses an analysis of the adoption of hypofractionated radiotherapy for early-stage invasive breast cancer.
For Breast Cancer Patients at Known BRCA Risk, a Role for Testing Prior to Surgery
June 17th 2014The majority of women with breast cancer who undergo the recommended genetic testing for BRCA1/2 mutations and test positive prior to undergoing surgery will change their surgical plan to include a more extensive procedure, a new study reports.
Nurses Design Proactive, Patient-Centered Program to Reduce Lymphedema Risk
June 11th 2014A pilot study of an educational and behavioral program conducted by researchers at the New York University College of Nursing has successfully reduced the risk of lymphedema in breast cancer patients who have undergone axillary lymph node dissection or sentinel lymph node biopsy.
Survey Finds More Inquiries to Genetic Counselors, Including From the "Worried-Well"
June 9th 2014A recent survey conducted by the National Society of Genetic Counselors (NSGC) showed a significant increase in patient calls and requests for testing and referrals from healthcare providers in the year following actress Angelina Jolie's announcement of her BRCA mutation status and subsequent double mastectomy.
Dosing Zoledronic Acid Less Often Doesn't Reduce Efficacy
June 3rd 2014Phase III trial results presented at the 2014 ASCO Annual Meeting showed that the dosing frequency of zoledronic acid (Zometa) can be reduced by 67% without compromising effectiveness in women with breast cancer and bone metastases, potentially lowering the risk of serious adverse events.
Key Role for Exemestane in Preventing Breast Cancer Recurrence in Premenopausal Women
June 2nd 2014Adjuvant exemestane reduced the relative risk of developing subsequent invasive cancer in hormone-receptor–positive (HR+) premenopausal women by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS)
Study Finds Survival and Fertility Benefit When Goserelin Augments Breast Cancer Chemo
June 1st 2014A new study presented at the 2014 ASCO Annual Meeting has found that adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.
Study Explores Racial/Ethnic Disparities in Incidence of Breast Cancer Subtypes
May 16th 2014An analysis of a large, nationwide dataset has revealed that regardless of their socioeconomic status, black women are nearly twice as likely to be diagnosed with triple-negative breast cancer (TNBC) and Asian/Pacific Islander women are more likely to be diagnosed with HER2-overexpressing breast cancer compared with white women.
Web-Based Program Helps Patients and Survivors to Manage Sexual Side Effects
May 15th 2014Sexual problems, such as loss of desire, failure to get aroused easily, and vaginal dryness and pain during sexual activity, are prevalent among breast cancer survivors, and they rarely go away without treatment.
Orientation Eases Stress and Helps Breast Cancer Patients Manage Neoadjuvant Regimens
May 8th 2014Nurses at the Rutgers Cancer Institute of New Jersey have developed a program to help patients with early-stage breast cancer to better understand and retain information about their presurgical treatments.
Archana Ajmera on Stomatitis Prevention During Metastatic Breast Cancer Treatment
May 3rd 2014Archana Ajmera, RN, MSN, WHNP-BC, ANP-BC, nurse practitioner, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses stomatitis prevention during everolimus/exemestane treatment for metastatic breast cancer.
Evidence-Based Approaches to Survivorship Care
April 30th 2014The number of cancer survivors in the United States is approaching 14 million, but that good news also means more attention must be paid to quality-of-life concerns for these individuals, as well as any long-term after effects of treatment.
USPSTF, ASCO Issue More Guidance on Genetic Testing Based on Family History
April 24th 2014Oncology practitioners now have several resources to consult for advice on genetic testing for their patients following the US Preventive Services Task Force (USPSTF) December 2013 update of its 2005 BRCA recommendations, plus new recommendations from the American Socieity of Clinical Oncology (ASCO) announced in February and published in the Journal of Clinical Oncology.
Helping Patients to Make Informed Decisions About Fertility Preservation
April 23rd 2014Studies show that young women diagnosed with breast cancer are not routinely receiving information about fertility preservation (FP) before their anticancer therapy begins, posing a missed opportunity for healthcare practitioners to provide women with options for improving their chances for a future pregnancy.
Leslie R. Schover on Vaginal Dryness and Pain in Breast Cancer Patients Treated With AIs
April 17th 2014Leslie R. Schover, PhD, clinical psychiatrist, professor, behavioral science, The University of Texas MD Anderson Cancer Center, discusses vaginal dryness and pain in patients with breast cancer treated with aromatase inhibitors.